14/#650 The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma. (4th December 2022)
- Record Type:
- Journal Article
- Title:
- 14/#650 The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma. (4th December 2022)
- Main Title:
- 14/#650 The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma
- Authors:
- Nunes, Rafael
Teixeira, Flavio
Goncalves, Bruna
Faloppa, Carlos
Kumagai, Lillian
Mantoan, Henrique
Badiglian-Filho, Levon
Guimaraes, Andrea
Costa, Alexandre Da
Baiocchi, Glauco - Abstract:
- Abstract : Objectives: To evaluate the role of PET/CT in predicting no residual disease (NRD) after secondary cytoreductive surgery (SCS) compared to MSK criteria, iMODEL and AGO Score. Methods: We analyzed 122 patients with platinum-sensitive ovarian carcinoma submitted to SCS between July 2008 and December 2021. We excluded patients that did not have PET/CT, without sufficient data and who received chemotherapy before SCS. We ultimately included 69 patients. Results: The median first relapse interval was 23 months (range, 6.05–104.2). Variables that correlated with NRD were PCI [OR 0.91 (0.83–0.99) 95%CI; p=0.044], ECOG0 [OR 8.0 (1.34–47.5) 95%CI; p=0.022] and number of lesions in PET/CT of ≤2 [OR 6.0 (1.24–28.9); 95%CI; p=0.026]. Considering patients with ≤2 lesions on the PET/CT, 92.3% had NRD. We recorded a sensitivity, PPV, NPV and accuracy of 85.7%, 92.3%, 33.3% and 81.2%, respectively. NRD would be achieved after fulfilling MSK criteria, iMODEL and AGO Score in 89.1%, 88.1% and 85.9%, respectively. The accuracy in prediction NRD of MSK criteria, iMODEL and AGO Score was 87%, 83.3% and 77.3%, respectively. PET/CT had a good agreement with AGO Score and iMODEL. The addition of PET/CT to the models increased the NRD rates (MSK+PET/CT, iMODEL+PET/CT and AGO+PET/CT NRDs in 92.2%, 91.8%, and 89.4%, respectively), however impaired their accuracy performance. Conclusions: We found NRD in 92.3% after the presence of ≤2 lesions in PET/CT with an accuracy of 81.2%. PET/CT didAbstract : Objectives: To evaluate the role of PET/CT in predicting no residual disease (NRD) after secondary cytoreductive surgery (SCS) compared to MSK criteria, iMODEL and AGO Score. Methods: We analyzed 122 patients with platinum-sensitive ovarian carcinoma submitted to SCS between July 2008 and December 2021. We excluded patients that did not have PET/CT, without sufficient data and who received chemotherapy before SCS. We ultimately included 69 patients. Results: The median first relapse interval was 23 months (range, 6.05–104.2). Variables that correlated with NRD were PCI [OR 0.91 (0.83–0.99) 95%CI; p=0.044], ECOG0 [OR 8.0 (1.34–47.5) 95%CI; p=0.022] and number of lesions in PET/CT of ≤2 [OR 6.0 (1.24–28.9); 95%CI; p=0.026]. Considering patients with ≤2 lesions on the PET/CT, 92.3% had NRD. We recorded a sensitivity, PPV, NPV and accuracy of 85.7%, 92.3%, 33.3% and 81.2%, respectively. NRD would be achieved after fulfilling MSK criteria, iMODEL and AGO Score in 89.1%, 88.1% and 85.9%, respectively. The accuracy in prediction NRD of MSK criteria, iMODEL and AGO Score was 87%, 83.3% and 77.3%, respectively. PET/CT had a good agreement with AGO Score and iMODEL. The addition of PET/CT to the models increased the NRD rates (MSK+PET/CT, iMODEL+PET/CT and AGO+PET/CT NRDs in 92.2%, 91.8%, and 89.4%, respectively), however impaired their accuracy performance. Conclusions: We found NRD in 92.3% after the presence of ≤2 lesions in PET/CT with an accuracy of 81.2%. PET/CT did not increase the accuracy performance of MSK criteria, iMODEL and AGO Score models. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 32(2022)Supplement 3
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 32(2022)Supplement 3
- Issue Display:
- Volume 32, Issue 3 (2022)
- Year:
- 2022
- Volume:
- 32
- Issue:
- 3
- Issue Sort Value:
- 2022-0032-0003-0000
- Page Start:
- A31
- Page End:
- A31
- Publication Date:
- 2022-12-04
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2022-igcs.58 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24964.xml